Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones

Diabetes, Obesity and Metabolism

Volumn 12, Issue 2, 2010, Pages 124-132

  Webb, D R ^a   Davies, M J ^a   Gray, L J ^b   Abrams, K R ^b   Srinivasan, B ^a   Das, S ^b   Taub, N ^b   Lawrence, I ^a   Sutton, S ^a   Khunti, K ^b  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

CIMT; Controlled trials; Diabetes; Pulse wave velocity; Systematic review; Thiazolidinediones

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TROGLITAZONE;

ANKLE BRACHIAL INDEX; AORTA ATHEROSCLEROSIS; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BRAIN ATHEROSCLEROSIS; CAROTID ARTERY PULSE; CLINICAL TRIAL; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 73349109150     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01122.x     Document Type: Article

References (42)

1. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004, 351:1106-1118.
2. Patel H, Srishanmuganathan J, Car J, Majeed A. Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991-2004. J Public Health 2007, 1:48-52.
3. Alexander CG, Niraj LS, Moloney BA, Stafford RS. National trends in the treatment of type 2 diabetes 1994-2007. Arch Intern Med 2008, 168:2088-2094.
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
5. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with Rosiglitazone: a meta-analysis. JAMA 2007, 298:1189-1195.
6. FDA Briefing Document 2007, 13-105. US Food and Drug Administration, Rockville, FDA
7. Kahn SE, Haffner SM, Heise MA. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
8. Home PD, Pocock SJ, Beck-Nielsen H. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005, 48:1726-1735.
9. Duckworth W, Abraira C, Moritz T. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
10. Gerstein HC, Miller ME, Byington RP. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes Study, Group
11. Gerstein HC, Yusuf S, Bosch J. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
12. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomised trials. JAMA 2007, 298:1180-1188.
13. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E. Secondary prevention of macrovascular events in patients with type 2 diabetes mellitus in the PROACTIVE study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a Randomised Controlled Trial. Lancet 2005, 366:1279-1289.
14. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129-1136.
15. Wagenknecht LE, Zaccaro D, Espeland MA, Karter AJ, O'Leary DH, Haffner SM. Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol 2003, 23:1035-1041.
16. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002, 106:2085-2090.
17. Roman MJ, Naqvi TZ, Gardin JM. American society of echocardiography report. Clinical application of non-invasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology. Vasc Med 2006, 11:201-211.
18. Laurent S, Cockcroft J, Van Borhel L. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605.
19. Moher D, Pharm B, Jones A, Cook DJ, Jadad AR, Moher M. Does quality or reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998, 352:609-613.
20. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003, 326:219.
21. Song F, Altman DG, Glenny AM, Deeks JJ. Validating the validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326:472.
22. Mazzone T, Meyer PM, Feinstein SB. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572-2581.
23. Mancia G, De Backer G, Dominiczak A. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007, 28:1462-1536.
24. Willum-Hansen T, Staessen JA, Torp-Pedersen C. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006, 113:664-670.
25. Nesto RW, Bell D, Bonow RO. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement from the American Heart Association and American Diabetes Association. Circulation 2003, 108:2941-2948.
26. Ogawa S, Takeuchi K, Ito S. Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab 2003, 88:3993-3996.
27. Turkmen Kemal Y, Guvener Demirag N, Yildirir A, Atar A, Dogruk Unal A, Biyiklioglu Z. Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus. Acta Diabetol 2007, 44:149-156.
28. Rahman S, Ismail AA, Ismail SB, Naing NN, Abdul Rahman AR. Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study. Eur J Clin Pharmacol 2007, 63:733-741.
29. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002, 25:708-711.
30. Sakamoto J, Kimura H, Moriyama S. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000, 278:704-711.
31. Kim SG, Ryu OH, Kim HY. Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Eur J Endocrinol 2006, 154:433-440.
32. Hodis HN, Mack WJ, Zheng L. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. Diabetes Care 2006, 29:1545-1553.
33. Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007, 261:293-305.
34. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998, 83:1818-1820.
35. Yokoyama H, Kuramitsu M, Yokota Y. Effect of combination therapy with pioglitazone and acarbose on the progression of early atherosclerosis in type 2 diabetes patients. J Jpn Diabetes Soc 2006, 49:197-204.
36. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001, 86:3452-3456.
37. Langenfeld MR, Forst T, Hohberg C. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005, 111:2525-2531.
38. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007, 153:445.e1-445.e6.
39. Nakamura T, Matsuda T, Kawagoe Y. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004, 53:1382-1386.
40. Satoh N, Ogawa Y, Usui T. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003, 26:2493-2499.
41. Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 2007, 56:1396-1401.
42. Watanabe I, Tani S, Anazawa T, Kushiro T, Kanmatsuse K. Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. Diabetes Res Clin Pract 2005, 68:104-110.